Mohamed Rawy Gives Clinical Tips for Management of Atrial Fibrillation
Mohamed Rawy, Hospital Pharmacist at Specialized Medical Center Hospital, shared on LinkedIn:
”Clinical tips for management of Atrial Fibrillation
Prevention of Stroke
– Eligible patients
– Balancing risks of Thrombosis and Bleeding using validated scores
– Oral anticogulants: Warfarin Vs NOAC
– Anticoagulation in specific population
– Active bleeding on anticogulant therapy and reversal agents
Rate Control
– Considerations for rate control
– Specific pharmacological agents: Acute rate control Vs Long term control
– AV node ablation
Rhythm Control
– Electrical and Pharmacological Cardioversion
– Considerations for anti arrhythmic drugs for maintenance of sinus rhythm
– Catheter or Surgical Ablation
Atrial fibrillation management in specific population
– AF in patients with ACS or CCS
– AF in patients with PAD
– AF in patients with AIS or Hemorrhagic stroke
– Post operative AF
– AF and HOCM
– AF and WPW
– AF in pregnancy
– AF in CKD Patients
– AF and Heart Failure”

Stay updated with Hemostasis Today.
-
Apr 22, 2026, 14:22Pradeep Natarajan: Can Polygenic Risk Scores Refine Risk Stratification in Secondary Prevention of CAD
-
Apr 22, 2026, 14:16Omar Adwan: Rare Genetic Disorders of Red Blood Cell Membrane Abnormalities
-
Apr 22, 2026, 14:10Alan Nurden: Pregnancy Challenges and Bleeding Risks in Inherited Platelet Disorders
-
Apr 22, 2026, 12:57Ali AlBahar: DNA Drives the Molecular Era of Blood Typing
-
Apr 22, 2026, 11:47We Are Excited to Introduce You to the 11th Editor-in-Chief Dr. Bob Löwenberg – Blood Journals Portfolio
-
Apr 22, 2026, 11:35Congratulations to Donald Arnold for Being Recognized with The ISTH 2026 Harold R. Roberts Award
-
Apr 22, 2026, 11:27Prashasti Dahiya: Key Molecular Insights on Thromboinflammation and Angiogenesis in Pediatric Cancer
-
Apr 22, 2026, 11:17Jack Hadfield: Understanding the Immune and Genetic Basis of VITT Post-COVID Vaccines
-
Apr 22, 2026, 07:56Shruti Kharat: Closing the Gap in Early Detection of Factor VIII Inhibitors